Acasă › Supraponderalitate › Kentucky
Studii clinice pentru Supraponderalitate în Kentucky
21 studii pentru Supraponderalitate caută participanți în Kentucky.
Orașe în Kentucky
Text oficial al studiului (în engleză)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- L-MARC Research Center /ID# 282008, Louisville
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT07752979Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- AMR Clinical - Lexington, Lexington
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT07685808A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Monroe Biomedical Research - Louisville, Louisville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07794579A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Monroe Biomedical Research, Louisville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07595549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Health Partners, Louisville
În curs de recrutareFaza 3
Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Norton Children's Endocrinology, Louisville
În curs de recrutareFaza 3
Vârste de la 6 la 17 · Toate sexele · Actualizat 24 sept. 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Health Partners, Louisville
În curs de recrutareFaza 3
Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- AMR Clinical, Lexington
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07392190Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Monroe Biomedical Research - Louisville, Louisville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Monroe Biomedical Research - Louisville, Louisville
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 22 sept. 2026 · NCT07589608A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Monroe Biomedical Research, Louisville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT07351045Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- L-MARC Research Center, Louisville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Monroe Biomedical Research - Louisville, Louisville
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 8 sept. 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Equity Medical - Bowling Green, Bowling Green
În curs de recrutareFaza 4
Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT06857942A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
- The Alliance for Multispecialty Research LLC AMR, Lexington
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT07745504Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Monroe Biomedical Research, Louisville
În curs de recrutareFaza 3
Vârste de la 18 la 99 · Toate sexele · Actualizat 3 sept. 2026 · NCT07684235AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Monroe Biomedical Research, LLC, Louisville
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT07509307Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Louisville
În curs de recrutareFaza 3
Vârste de la 18 la 79 · Toate sexele · Actualizat 10 aug. 2026 · NCT07654361Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
- University of Kentucky, Lexington
În curs de recrutareStudiu observațional
Vârste de la 12 la 17 · Toate sexele · Actualizat 21 iul. 2026 · NCT06967389A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
- Monroe Biomedical Research, Louisville
În curs de recrutareFaza 2
Vârste de la 18 la 60 · Toate sexele · Actualizat 22 iun. 2026 · NCT07570758A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Lexington
În curs de recrutareFaza 1
Vârste de la 18 la 65 · Toate sexele · Actualizat 9 iun. 2026 · NCT07142707Sursă: ClinicalTrials.gov, date preluate la 3 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.